E

Entrada Therapeutics

Develops intracellular therapeutics using endosomal escape

Associate Director - Analytical Development & Quality Control

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • A Ph.D. in Organic Chemistry, Analytical Chemistry, or a related discipline.
  • At least 6 years of late-stage and commercial analytical development and quality control experience in the biotechnology or pharmaceutical industry.
  • Strong knowledge of analytical development and quality control requirements for late-stage and commercial oligonucleotide programs, especially PMO and PPMO.
  • Extensive experience with regulatory filings, including IND, IMPD, NDA, and MAA.
  • Strong knowledge and hands-on experience with ICH, FDA, EMA, USP, and Ph. Eur. regulatory requirements and guidelines for quality control of late-stage oligonucleotide drug product manufacturing.
  • Extensive knowledge of current Good Manufacturing Practice regulations and guidelines.
  • Experience contributing to product quality risk assessments to identify critical quality attributes and develop associated limits and specifications.
  • Experience contributing to product quality risk assessments to identify critical quality attributes and develop associated limits and specifications.
  • Strong written and verbal communication and interpersonal skills.
  • Strong attention to detail and ability to deliver results in line with project and team objectives.
  • Ability to handle multiple high-priority tasks in parallel to meet organizational goals.

Responsibilities

  • Partner with internal cross-functional teams and external contract development and manufacturing organizations to provide analytical development and quality control support for late-stage activities, process performance qualification campaigns, and commercial manufacturing.
  • Develop and implement analytical development and quality control strategies to support regulatory submissions and commercial readiness.
  • Lead analytical method lifecycle management, including method transfer, validation, verification, comparability assessments, and ongoing method performance monitoring.
  • Establish, scientifically justify, and maintain analytical specifications and sampling plans throughout the product lifecycle.
  • Author, review, and approve analytical development and quality control sections of regulatory submissions, including INDs, IMPDs, NDAs, MAAs, and post-approval supplements.
  • Provide analytical development and quality control expertise for health authority inspections and responses, ensuring documentation complies with current ICH, FDA, EMA, and other applicable global regulatory requirements.
  • Serve as the analytical development and quality control subject matter expert during regulatory inspections, partner audits, and quality system assessments, representing the functions and ensuring inspection readiness.
  • Collaborate with drug substance and drug product development and manufacturing, Quality Assurance, and Regulatory Affairs to support product development, technology transfer, commercialization, and lifecycle management.
  • Establish and monitor key analytical development and quality control performance metrics and drive continuous improvement initiatives to enhance quality, regulatory compliance, operational efficiency, and inspection preparedness.

Desired Qualifications

  • Strong knowledge of requirements for late-stage and commercial oligonucleotide programs, especially PMO and PPMO, is highly desired.
  • PMO and PPMO experience is a strong plus.

About the Company

Entrada Therapeutics

Develops intracellular therapeutics using endosomal escape

Entrada Therapeutics focuses on developing a new class of medicines to treat devastating diseases by delivering therapies inside cells. Its core technology, the Endosomal Escape Vehicle (EEV) platform, helps drugs escape from endosomes—cellular compartments that often trap or degrade treatments—so they can reach intracellular targets. The product pipeline centers on EEV-therapeutics, including candidates for Duchenne muscular dystrophy and other neuromuscular diseases, with ENTR-601-45 currently cleared by UK and EU regulators to begin clinical trials. What sets Entrada apart is its explicit emphasis on enabling intracellular delivery to access targets that were previously hard to treat, using a platform-agnostic delivery approach that can work with a range of therapeutics such as oligonucleotides. The company’s goal is to advance multiple EEV-therapeutics through clinical development to address rare and other hard-to-treat diseases and reach patients who need new treatment options.

Company size
201-500
Company stage
IPO
Headquarters
Boston, MA
Founded
2016

Recently Posted Jobs

Explore more opportunities at Entrada Therapeutics

See more jobs